This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
S. Stewart, I. Ekman, T. Ekman, A. Oden and A. Rosengren, Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004), Circ. Cardiovasc. Qual. Outcomes3(6) (2010) 573–580; https://doi.org/10.1161/CIRCOUTCOMES.110.957571Search in Google Scholar
T. A. McDonagh, M. Metra, M. Adamo, R. S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, J. G. F. Cleland, A. J. S. Coats, M. G. Crespo-Leiro, D. Farmakis, M. Gi-lard, S. Heymans, A. W. Hoes, T. Jaarsma, E. A. Jankowska and A. K. Skibelund, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur. Heart J.42(36) (2021) 3599–3726; https://doi.org/10.1093/eurheartj/ehab368Search in Google Scholar
E. Lonn, Dose response of ACE inhibitors: implications of the SECURE trial, Trials2(4) (2001) 155–159; https://doi.org/10.1186/cvm-2-4-155Search in Google Scholar
D. S. Roffman, High-versus low-dose ACE inhibitor therapy in chronic heart failure. Ann. Pharmacother.38(5) (2004) 831–838; https://doi.org/10.1345/aph.1C402Search in Google Scholar
E. R. Debusmann, J. O. Pujadas, W. Lahn, R. Irmisch, F. Jane, T. S. Kuan, J. Mora, U. Walter, H. G. Eckert, P. Hajdu and H. Metzger, Influence of renal function on the pharmacokinetics of ramipril (HOE 498), Am. J. Cardiol.59(10) (1987) 70D–78D; https://doi.org/10.1016/0002-9149(87)90057-9Search in Google Scholar
J. M. van Griensven, R. C. Schoemaker, A. F. Cohen, H. G. Luus, M. Seibert-Grafe and H. J. Rothig, Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril, Eur. J. Clin. Pharmacol.47(6) (1995) 513–518. https://doi.org/10.1007/BF00193704Search in Google Scholar
D. G. Levitt and R. C. Schoemaker, Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat, BMC Clin. Pharmacol.6(1) (2006); https://doi.org/10.1186/1472-6904-6-1Search in Google Scholar
B. Beermann, O. Nyquist, C. Hoglund, K. A. Jacobsson, U. Naslund and M. Jensen-Urstad, Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study, Eur. J. Clin. Pharmacol45(3) (1993) 241–246; https://doi.org/10.1007/BF00315390Search in Google Scholar
H. Schunkert, J. Kindler, M. Gassmann, W. Lahn, R. Irmisch, E. Ritz, E. R. Debusmann, J. O. Puja das, K. M. Koch and H. G. Sieberth, Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency, Eur. J. Clin. Pharmacol.37(3) (1989) 249–256; https://doi.org/10.1007/BF00679779Search in Google Scholar
M. Verho, C. Luck, W. J. Stelter, B. Rangoonwala and N. Bender, Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man, Curr. Med. Res. Opin.13(5) (1995) 264–273; https://doi.org/10.1185/03007999509111551Search in Google Scholar
U. Gerckens, E. Grube, T. Mengden, H. Sigel, W. L. Wagner, T. Lahn, R. Irmisch and H. Metzger, Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV), J. Cardiovasc. Pharmacol.13 Suppl 3 (1989) S49–51; https://doi.org/10.1097/00005344-198900133-00012Search in Google Scholar
B. Heintz, M. Verho, D. Brockmeier, G. Luckel, S. Maigatter, H. G. Sieberth, B. Rangoonwala and N. Bender, Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure, J. Cardiovasc. Pharmacol.22 Suppl 9 (1993) S36–42.Search in Google Scholar
G. Loncar, J. Springer, M. Anker, W. Doehner and M. Lainscak, Cardiac cachexia: hic et nunc, J. Cachexia Sarcopenia Muscle7(3) (2016) 246–60; https://doi.org/10.1002/jcsm.12118Search in Google Scholar
S. Khan and A. Shahzadi, Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review, Drug Metab. Rev.51(1) (2019) 1–11. https://doi.org/10.1080/03602532.2018.1508226Search in Google Scholar
K. Trobec, M. Kerec Kos, S. von Haehling, J. Springer, S. D. Anker and M. Lainscak, Pharmacokinetics of drugs in cachectic patients: a systematic review, PLoS One8(11) (2013) e79603 (10 pages); https://doi.org/10.1371/journal.pone.0079603Search in Google Scholar
S. Janmahasatian, S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne and B. Green, Quantification of lean bodyweight, Clin. Pharmacokinet.44(10) (2005) 1051–1065; https://doi.org/10.2165/00003088-200544100-00004Search in Google Scholar
L. I. Cortinez, B. J. Anderson, N. H. Holford, V. Puga, N. de la Fuente, H. Auad, S. Solari, F. A. Allende and M. Ibacache, Dexmedetomidine pharmacokinetics in the obese. Eur. J. Clin. Pharmacol.71(12) (2015) 1501–1508; https://doi.org/10.1007/s00228-015-1948-2Search in Google Scholar
I. Janssen, R. N. Baumgartner, R. Ross, I. H. Rosenberg and R. Roubenoff, Skeletal muscle cut-points associated with elevated physical disability risk in older men and women, Am. J. Epidemiol.159(4) (2004) 413–421; https://doi.org/10.1093/aje/kwh058Search in Google Scholar
I. Janssen, S. B. Heymsfield, R. N. Baumgartner and R. Ross, Estimation of skeletal muscle mass by bioelectrical impedance analysis, J. Appl. Physiol.89(2) (2000) 465–471; https://doi.org/10.1152/jappl.2000.89.2.465Search in Google Scholar
O. González, M. E. Blanco, G. Iriarte, L. Bartolomé, M. I. Maguregui and R. M. Alonso, Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect, J. Chromatogr. A1353 (2014) 10–27; https://doi.org/10.1016/j.chroma.2014.03.077Search in Google Scholar
C. Ghosh, Relative matrix effects: A step forward using standard line slopes and ANOVA analysis, Arab. J. Chem.12(7) (2019) 1378–1386; https://doi.org/10.1016/j.arabjc.2014.11.019Search in Google Scholar
A. M. Alvarez and D. Mukherjee, Liver abnormalities in cardiac diseases and heart failure, Int. J. Angiol.20(3) (2011)135–142; https://doi.org/10.1055/s-0031-1284434Search in Google Scholar
M. D. Samsky, C. B. Patel, T. A. DeWald, A. D. Smith, G. M. Felker, J. G. Rogers and A. F. Hernandez, Cardiohepatic interactions in heart failure: an overview and clinical implications, J. Am. Coll. Cardiol.61(24) (2013) 2397–2405; https://doi.org/10.1016/j.jacc.2013.03.042Search in Google Scholar
T. Narumi, T. Watanabe, S. Kadowaki, T. Takahashi, M. Yokoyama, D. Kinoshita, Y. Honda, A. Funayama, S. Nishiyama, H. Takahashi, T. Arimoto, T. Shishido, T. Miyamoto and I. Kubota, Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure, Eur. J. Intern. Med.26(2) (2015) 118–122; https://doi.org/10.1016/j.ejim.2015.01.008Search in Google Scholar
N. H. Uszko-Lencer, F. Bothmer, P. E. van Pol and A. M. Schols, Measuring body composition in chronic heart failure: a comparison of methods, Eur. J. Heart Fail8(2) (2006) 208–214; https://doi.org/10.1016/j.ejheart.2005.07.007Search in Google Scholar
P. L. Toutain and H. P. Lefebvre, Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors, J. Vet. Pharmacol. Ther.27(6) (2004) 515–525; https://doi.org/10.1111/j.1365-2885.2004.00601.xSearch in Google Scholar
R. Thomsen, H. B. Rasmussen, K. Linnet and INDICES Consortium, In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors, Drug Metab. Dispos.42(1) (2014) 126–133; https://doi.org/10.1124/dmd.113.053512Search in Google Scholar
W. J. Gilchrist, K. Beard, P. Manhem, E. M. Thomas, J. I. Robertson and S. G. Ball, Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients, Am. J. Cardiol.59(10) (1987) 28D–32D; https://doi.org/10.1016/0002-9149(87)90049-XSearch in Google Scholar
R. Ogawa, J. M. Stachnik and H. Echizen, Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally), Clin. Pharmacokinet.53(12) (2014) 1083–1114; https://doi.org/10.1007/s40262-014-0189-3Search in Google Scholar